[Phenytoin hypersensitivity syndrome].
Diphenylhydantoine is a drug frequently used in the treatment of epilepsia. In rare occasions, it produces a mulsisystemic manifestation characterized by fever, lymphadenopathy, hepatitis, eosinophilia and desquamative cutaneous eruption, which typically develops within 4-8 weeks after the beginning of the treatment. Mortality rates may reach up to 40% in patients with severe hepatic affection, although the response to steroid therapy is usually frequent. We present the case of a patient which developed a syndrome of hypersensibility to diphenylhydantoine with mononucleosic manifestations, icteric hepatitis and exfoliative dermatitis, who completely recovered a few days after his hospitalization.
García-Samaniego
J
J
Servicio de Gastroenterología, Instituto de Salud Carlos III, Madrid.
Soriano
V
V
Soto
J
J
Muñoz
F
F
D000293:Adolescent; D004342:Drug Hypersensitivity / Q000209:etiology*; D006801:Humans; D008297:Male; D010672:Phenytoin / Q000009:adverse effects*; D013577:Syndrome
D010672:Phenytoin
Síndrome de hipersensibilidad a fenitoína.